Bristol-Myers Squibb (BMY) FY2015 results: revenue $16.6 billion, up 4.3% on the year
Bristol-Myers Squibb Co. (BMY) reported revenue of $16.6 billion for fiscal 2015, the year ended 31 December 2015, up 4.3% on the year before. Net income was $1.6 billion, down 21.9%, and diluted earnings per share $0.93. The figures are the company's own, from the 10-K it filed with the SEC on 12 February 2016.
Revenue
$16.6 billion
+4.3% on the year
FY2008FY2015
Operating margin
12.5%
15.0% a year earlier
FY2008FY2015
Net income
$1.6 billion
-21.9% on the year
FY2008FY2015
Diluted EPS
$0.93
-22.5% on the year
FY2008FY2015
this yearthe year beforeHover a bar for its figure.
The year in brief
Income statement (profit and loss)
$ million
FY2015
FY2014
FY2013
On the year
Last 8 years
Revenue
16,560
15,879
16,385
+4.3%
Cost of revenue
3,909
3,932
4,619
-0.6%
Gross profit
12,651
11,947
11,766
+5.9%
Gross margin
76.4%
75.2%
71.8%
Research and development
5,920
4,534
3,731
+30.6%
Selling, general and administrative
4,841
4,822
4,939
+0.4%
Operating income
2,077
2,381
2,891
-12.8%
Operating margin
12.5%
15.0%
17.6%
Interest expense
184
203
199
-9.4%
Pre-tax income
2,077
2,381
2,891
-12.8%
Income tax
446
352
311
+26.7%
Effective tax rate
21.5%
14.8%
10.8%
Net income
1,565
2,004
2,563
-21.9%
Net margin
9.5%
12.6%
15.6%
Diluted EPS
$0.93
$1.20
$1.54
-22.5%
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2015
FY2014
FY2013
On the year
Last 8 years
Operating cash flow
2,105
3,148
3,545
-33.1%
Capital expenditure
820
526
537
+55.9%
Free cash flow
1,285
2,622
3,008
-51.0%
Free cash flow margin
7.8%
16.5%
18.4%
Cash from investing
-1,572
1,216
-572
Cash from financing
-3,624
-2,437
-1,068
Depreciation and amortisation
376
467
763
-19.5%
Share-based compensation
235
213
191
+10.3%
Buybacks
n/a
n/a
433
Dividends paid
2,477
2,398
2,309
+3.3%
Dividend per share
$1.49
$1.45
$1.41
+2.8%
Diluted shares, weighted
1,679m
1,670m
1,662m
+0.5%
Balance sheet
$ million
FY2015
FY2014
FY2013
On the year
Last 8 years
Shareholders' equity
14,266
14,852
15,154
-3.9%
Non-controlling interest
158
131
82.0
+20.6%
Debt
6,689
7,832
8,340
-14.6%
Other liabilities
10,635
10,934
15,016
-2.7%
Total liabilities and equity
31,748
33,749
38,592
-5.9%
Fixed assets
4,412
4,417
4,579
-0.1%
Goodwill
6,881
7,027
7,096
-2.1%
Intangible assets
1,419
1,753
2,318
-19.1%
Investments
6,545
6,272
4,686
+4.4%
Cash and equivalents
2,385
5,571
3,586
-57.2%
Receivables
2,948
2,100
1,690
+40.4%
Inventory
1,221
1,560
1,498
-21.7%
Other assets
5,937
5,049
13,139
+17.6%
Total assets
31,748
33,749
38,592
-5.9%
10-K for the year ended 31 December 2015, filed 12 February 2016: the filing.